Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from VYNE Therapeutics ( (VYNE) ).
On January 30, 2026, VYNE Therapeutics, its wholly owned subsidiary Yarrow Merger Sub Corp., and Yarrow Bioscience amended their December 17, 2025 merger agreement to refine how equity will be issued to Yarrow stockholders in the planned transaction. The amendment allows VYNE to issue pre-funded warrants instead of common shares to any Yarrow holder whose merger consideration would push their beneficial ownership of VYNE stock above a specified limit, with the warrants exercisable for the excess amount that would otherwise breach that cap, and it also clarifies that a planned pre-closing dividend from VYNE may be paid not only on outstanding common stock but also on the common shares underlying certain existing VYNE warrants as of the dividend record date, providing greater precision on post-deal ownership structure and entitlement to dividends for current and incoming stakeholders.
The most recent analyst rating on (VYNE) stock is a Hold with a $0.61 price target. To see the full list of analyst forecasts on VYNE Therapeutics stock, see the VYNE Stock Forecast page.
Spark’s Take on VYNE Stock
According to Spark, TipRanks’ AI Analyst, VYNE is a Neutral.
The score is held down primarily by very weak fundamentals (minimal revenue, large losses, and heavy cash burn), despite a debt-light balance sheet. Technicals are moderately supportive with improving momentum, and the merger/financing news is a notable positive, but valuation remains challenged due to ongoing losses and no dividend data.
To see Spark’s full report on VYNE stock, click here.
More about VYNE Therapeutics
VYNE Therapeutics Inc. is a Delaware-based biopharmaceutical company focused on developing and commercializing therapeutics, operating through corporate structures that include wholly owned subsidiaries such as Yarrow Merger Sub Corp. as it pursues strategic transactions to expand its pipeline and capabilities.
Average Trading Volume: 5,515,713
Technical Sentiment Signal: Sell
Current Market Cap: $18.8M
For an in-depth examination of VYNE stock, go to TipRanks’ Overview page.